KRAS G12C mutation was present in eight patients overall – six patients in the STS cohort, one in the uterine sarcoma cohort (undifferentiated uterine sarcoma), and one in the breast sarcoma cohort (angiosarcoma). Here, KRAS is linked to uterine corpus sarcoma.